We study mechanisms of action of immunotherapies, including immune checkpoint inhibitors, depleting antibodies, immunomodulatory drugs, CELMoDS, and synthetic cytokines. We test these therapies in our clinically relevant, immunocompetent mouse models to identify non-overlapping mechanisms. This allows us to design rational combination approaches. A couple of these combination approaches have entered clinical trials, and we will now apply this approach to understand how to best sequence different immunotherapies, including T cell redirection approaches.

Minnie et al. JCI, 2023